24,019 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Acquired by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky acquired a new position in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 24,019 shares of the company's stock, valued at approximately $1,038,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Barclays PLC increased its holdings in Scholar Rock by 103.4% in the third quarter. Barclays PLC now owns 165,449 shares of the company's stock valued at $1,324,000 after buying an additional 84,118 shares in the last quarter. Geode Capital Management LLC increased its stake in Scholar Rock by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock valued at $12,361,000 after purchasing an additional 120,489 shares in the last quarter. Exome Asset Management LLC acquired a new position in Scholar Rock during the third quarter worth $1,115,000. JPMorgan Chase & Co. boosted its position in Scholar Rock by 1.0% during the third quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock worth $310,000 after purchasing an additional 379 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after buying an additional 269 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wedbush restated an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a report on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $42.67.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Tracey Sacco sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $32.83, for a total transaction of $164,150.00. Following the completion of the sale, the insider now owns 71,750 shares in the company, valued at $2,355,552.50. This trade represents a 6.51 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Edward H. Myles sold 7,809 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $287,605.47. Following the transaction, the chief financial officer now directly owns 140,740 shares of the company's stock, valued at approximately $5,183,454.20. This represents a 5.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 255,231 shares of company stock worth $9,220,236 over the last ninety days. 13.30% of the stock is currently owned by corporate insiders.

Scholar Rock Price Performance

Scholar Rock stock traded up $0.15 during midday trading on Friday, reaching $32.91. 1,339,190 shares of the company were exchanged, compared to its average volume of 1,260,274. The company has a market capitalization of $3.12 billion, a price-to-earnings ratio of -14.00 and a beta of 0.56. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The firm's 50-day simple moving average is $32.26 and its 200-day simple moving average is $35.83. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.